

Stefano Luminari

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1651240/stefano-luminari-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

250
papers

7,499
citations

43
h-index

82
g-index

268
ext. papers

8,822
ext. citations

3.8
avg, IF

5.04
L-index

#	Paper	IF	Citations
250	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667
249	Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4555-62	2.2	483
248	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2419-29	59.2	428
247	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 331-344	59.2	378
246	Pure red-cell aplasia and epoetin therapy. <i>New England Journal of Medicine</i> , 2004 , 351, 1403-8	59.2	338
245	Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. <i>Journal of Clinical Oncology</i> , 2013 , 31, 240-6	2.2	216
244	ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 805-11	2.2	206
243	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1506-13	2.2	193
242	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006 , 91, 475-81	6.6	190
241	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014 , 99, 1107-13	6.6	179
240	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3618-3626	2.2	162
239	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1113-22	8.8	114
238	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014 , 25, 1404-1410	10.3	114
237	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015 , 126, 950-6	2.2	111
236	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014 , 1, e17-27	14.6	108
235	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , 2016 , 127, 1531-8	2.2	105
234	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013 , 24, 2108-12	10.3	104

233	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012 , 156, 346-53	4.5	101
232	Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3848-53	2.2	92
231	High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2320-5	2.2	90
230	Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Blood</i> , 2005 , 106, 3343-7	2.2	83
229	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 689-696	2.2	81
228	Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007 , 48, 56-64	1.9	74
227	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1175-81	2.2	74
226	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008 , 93, 398-404	6.6	73
225	Nonpegylated liposomal doxorubicin (Myocet™) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. <i>Annals of Oncology</i> , 2010 , 21, 1492-1499	10.3	72
224	Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. <i>British Journal of Haematology</i> , 2013 , 163, 40-6	4.5	71
223	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. <i>Clinical Cancer Research</i> , 2014 , 20, 6398-405	12.9	69
222	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. <i>Blood</i> , 1999 , 93, 1330-1337	2.2	68
221	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3292-9	2.2	66
220	Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4662-6	2.2	64
219	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013 , 98, 1232-6	6.6	57
218	Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. <i>Haematologica</i> , 2011 , 96, 720-8	6.6	57
217	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012 , 53, 581-8	1.9	56
216	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011 , 22, 689-695	10.3	56

215	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014 , 55, 38-43	1.9	54
214	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014 , 25, 442-7	10.3	51
213	GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. <i>Cytotherapy</i> , 2010 , 12, 466-77	4.8	50
212	Cancer incidence in people with AIDS in Italy. <i>International Journal of Cancer</i> , 2010 , 127, 1437-45	7.5	50
211	Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. <i>Blood</i> , 2001 , 98, 781-6	2.2	50
210	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014 , 99, 489-96	6.6	46
209	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007 , 109, 2077-82	6.4	46
208	Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas. <i>Annals of Oncology</i> , 2010 , 21, 855-859	10.3	43
207	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 544-562	10.3	42
206	Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012 , 120, 3858-60	2.2	42
205	Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4227-33	2.2	38
204	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 53-7	1.9	36
203	Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. <i>Hematological Oncology</i> , 2007 , 25, 189-97	1.3	36
202	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006 , 77, 387-94	3.8	35
201	Transformed follicular lymphoma. <i>Annals of Hematology</i> , 2018 , 97, 17-29	3	33
200	FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma. <i>Blood</i> , 1998 , 92, 2987-2989	2.2	33
199	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. <i>Blood</i> , 2018 , 131, 2449-2453	2.2	31
198	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. <i>Haematologica</i> , 2017 , 102, 1748-1757	6.6	31

197	Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007 , 92, 1482-8	6.6	30
196	T-cell lymphomas in South america and europe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012 , 34, 42-7		29
195	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016 , 101, e66-8	6.6	28
194	Infections occurring in adult patients receiving mechanical circulatory support: the two-year experience of an Italian National Referral Tertiary Care Center. <i>Medicina Intensiva</i> , 2013 , 37, 468-75	1.2	27
193	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2014 , 166, 140-2	4.5	27
192	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014 , 93, 221-231	3	27
191	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the. <i>Haematologica</i> , 2018 , 103, 1345-1350	6.6	26
190	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. <i>Blood</i> , 2015 , 126, 733-8	2.2	26
189	Bendamustine salvage therapy for T cell neoplasms. <i>Annals of Hematology</i> , 2013 , 92, 1249-54	3	25
188	Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). <i>Journal of General Internal Medicine</i> , 2012 , 27, 1697-703	4	25
187	Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow. <i>Annals of Hematology</i> , 1998 , 76, 81-3	3	24
186	High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. <i>Haematologica</i> , 2009 , 94, 146-8	6.6	23
185	A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. <i>American Journal of Hematology</i> , 2008 , 83, 349-54	7.1	23
184	Follicular lymphoma - treatment and prognostic factors. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012 , 34, 54-9		23
183	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. <i>Leukemia Research</i> , 2013 , 37, 619-23	2.7	21
182	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011 , 90, 401-8	3	21
181	Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. <i>Leukemia</i> , 2000 , 14, 446-8	10.7	21
180	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1214-1222	2.2	21

179	Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1249-1254	8.9	20
178	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018 , 36, 68-75	1.3	20
177	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019 , 134, 798-801	2.2	20
176	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019 , 24, e1236-e1250	5.7	20
175	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011 , 52, 823-32	1.9	20
174	Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1459-65	2.2	20
173	Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. <i>Haematologica</i> , 2004 , 89, 973-8	6.6	20
172	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3281-7	1.9	19
171	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis and Haemostasis</i> , 2017 , 117,	7	19
170	Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 367-73	1.9	19
169	BCL10 gene mutations rarely occur in lymphoid malignancies. <i>Leukemia</i> , 2000 , 14, 905-8	10.7	19
168	The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Bone Marrow Transplantation</i> , 2006 , 37, 283-8	4.4	18
167	Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , 2005 , 106, 5057-5057	2.2	17
166	PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S177	8.2	16
165	Clinical characteristics of erythropoietin-associated pure red cell aplasia. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 467-72	4.2	16
164	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2298-2303	2.3	15
163	Fertility in female survivors of Hodgkin's lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012 , 34, 48-53		15
162	The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). <i>Physica Medica</i> , 2016 , 32, 651-6	2.7	15

161	The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study. <i>BMC Cancer</i> , 2018 , 18, 1069	4.8	15
160	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020 , 126, 78-90	7.5	14
159	Prognosis of follicular lymphomas. <i>Hematological Oncology</i> , 2006 , 24, 64-72	1.3	14
158	Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7574-7574	2.2	14
157	Texture analysis and multiple-instance learning for the classification of malignant lymphomas. <i>Computer Methods and Programs in Biomedicine</i> , 2020 , 185, 105153	6.9	14
156	Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2319-2327	1.9	13
155	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013 , 54, 62-8	1.9	13
154	Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. <i>Leukemia and Lymphoma</i> , 2006 , 47, 473-9	1.9	13
153	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018 , 103, 849-856	6.6	12
152	Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. <i>Hematological Oncology</i> , 2012 , 30, 194-9 ¹⁻³		12
151	Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 481-9	4.2	12
150	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 136-140	7.8	12
149	Germinotropic lymphoproliferative disorder: a systematic review. <i>Annals of Hematology</i> , 2020 , 99, 2243-2253	3	11
148	Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry. <i>Hematological Oncology</i> , 2015 , 33, 147-51	1.3	11
147	Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma. <i>Hematology Reports</i> , 2011 , 3, e4	0.9	11
146	Prognostic factors in low-grade non-Hodgkin lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009 , 4, 202-10	4.4	11
145	Survival of cancer patients in Italy. <i>Epidemiologia E Prevenzione</i> , 2017 , 41, 1-244	1.1	11
144	Reassessments of ESAs for cancer treatment in the US and Europe. <i>Oncology</i> , 2010 , 24, 260-8	1.8	11

143	Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016 , 101, e139-41	6.6	10
142	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014 , 25, 2398-2404	10.3	10
141	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Annals of Hematology</i> , 2011 , 90, 323-30	3	10
140	Prognostic tools in follicular lymphomas. <i>Expert Review of Hematology</i> , 2009 , 2, 549-62	2.8	10
139	Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2564-71	1.9	9
138	Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. <i>Oncologist</i> , 2019 , 24, 537-548	5.7	9
137	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 37-40	3.6	9
136	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 880-7	1.9	8
135	Prognostic assessment in patients with indolent B-cell lymphomas. <i>Scientific World Journal, The</i> , 2012 , 2012, 107892	2.2	8
134	Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 138-44		8
133	Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review. <i>Cancers</i> , 2021 , 13,	6.6	8
132	Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. <i>American Journal of Hematology</i> , 2009 , 84, 850-2	7.1	7
131	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006 , 76, 217-29	3.8	7
130	Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1933-8	1.9	7
129	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101234	2.2	7
128	Nonpegylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020 , 38, 478-486 ¹³		6
127	Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. <i>Hematological Oncology</i> , 2013 , 31, 72-8	1.3	6
126	ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. <i>Annals of Oncology</i> , 2008 , 19, 763-8	10.3	6

125	Home care of acute leukaemia patients: From active therapy to end-of-life and palliative care. The 3-year experience of a single centre. <i>European Journal of Haematology</i> , 2019 , 102, 424-431	3.8	5
124	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019 , 60, 2890-2898	1.9	5
123	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009 , 115, 1906-13	6.4	5
122	Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. <i>Oncology Reports</i> , 2009 , 21, 1029-35	3.5	5
121	Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2003 , 121, 772-4	4.5	5
120	Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002 , 43, 1795-801	1.9	5
119	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019 , 134, 398-398	2.2	5
118	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021 , 13,	6.6	5
117	Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. <i>Hematological Oncology</i> , 2017 , 35, 861-863	1.3	4
116	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015 , 100, 517-24	6.6	4
115	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1689-96	1.9	4
114	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. <i>British Journal of Haematology</i> , 2003 , 123, 747-8; author reply 748	4.5	4
113	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. <i>Blood</i> , 2019 , 134, 124-124	2.2	4
112	Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL. <i>Blood</i> , 2008 , 112, 3050-3050 ²	2.2	4
111	Low Suvmax Measured on Baseline FDG-PET/CT and Elevated κ Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies. <i>Blood</i> , 2016 , 128, 1101-1101	2.2	4
110	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8507-8507	2.2	4
109	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8552-8552	2.2	4
108	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. <i>Hematological Oncology</i> , 2021 , 39, 293-303	1.3	4

107	Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma Patients. <i>Frontiers in Nutrition</i> , 2021 , 8, 620696	6.2	4
106	FDG-PET(CT)-adapted trials in non-Hodgkin lymphoma. <i>Clinical and Translational Imaging</i> , 2015 , 3, 295-307		3
105	Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 189, e49-e52	4.5	3
104	Reply to H.J.A. Adams et al and E. Laffon et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 920-923	2.2	3
103	Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications. <i>Hematological Oncology</i> , 2018 , 36, 723-732	1.3	3
102	Bridging the gap between epidemiology and clinical research in lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1855-6	1.9	3
101	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015 , 90, 56-61	7.1	3
100	Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012 , 53, 406-10	1.9	3
99	The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). <i>Annals of Oncology</i> , 2006 , 17, 676-82	10.3	3
98	Analysis of BCL-10 gene mutations in ovarian cancer cell lines. <i>Annals of Oncology</i> , 1999 , 10, 1259	10.3	3
97	Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study. <i>Blood</i> , 2007 , 110, 1293-1293	2.2	3
96	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. <i>Blood</i> , 2014 , 124, 3088-3088	2.2	3
95	R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8006-8006	2.2	3
94	A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. <i>Clinical Cancer Research</i> , 2020 , 26, 373-383	12.9	3
93	Early palliative care in haematological patients: a systematic literature review. <i>BMJ Supportive and Palliative Care</i> , 2020 , 10, 395-403	2.2	3
92	Veno-occlusive disease nurse management: development of a dynamic monitoring tool by the GITMO nursing group. <i>Ecancermedicalscience</i> , 2016 , 10, 661	2.7	3
91	Case studies of elderly patients with non-Hodgkin's lymphoma. <i>Hematology Reports</i> , 2011 , 3, e7	0.9	2
90	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010 , 51, 422-9	1.9	2

89	Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma. <i>Blood</i> , 2020 , 136, 24-25	2.2	2
88	R-CHOP vs R-mini-CEOP in Elderly Patients with Diffuse Large B Cell Lymphoma: An Interim Report from Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2005 , 106, 4729-4729	2.2	2
87	Early Response to a Short Course of Induction Chemotherapy Overcomes the Prognostic Role of IPI in Patients with Aggressive NHL. Preliminary Results of the GISL LA05 Trial.. <i>Blood</i> , 2006 , 108, 2434-2434	2.2	2
86	Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL). <i>Blood</i> , 2008 , 112, 2602-2602	2.2	2
85	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020 , 95, 1473-1478	7.1	2
84	The use of frailty assessments in treating older adults with aggressive lymphomas. <i>British Journal of Haematology</i> , 2021 , 194, 677-685	4.5	2
83	Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. <i>British Journal of Haematology</i> , 2019 , 185, 944-947	4.5	2
82	Early palliative care versus standard care in haematologic cancer patients at their last active treatment: study protocol of a feasibility trial. <i>BMC Palliative Care</i> , 2020 , 19, 53	3	2
81	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 192, 1011-1014	4.5	2
80	Advances in Treatment of Follicular Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020 , 26, 231-240	2.2	1
79	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 247-51		1
78	Splenosis peritonei. <i>British Journal of Haematology</i> , 2003 , 123, 378	4.5	1
77	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , 2018 , 132, 393-393	2.2	1
76	Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2019 , 134, 2880-2880	2.2	1
75	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2007 , 110, 3429-3429	2.2	1
74	Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas. <i>Blood</i> , 2010 , 116, 1801-1801		1
73	Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.. <i>Blood</i> , 2010 , 116, 2821-2821	2.2	1
72	FDG-PET and Hodgkin Lymphoma: Are We Ready for a Functional Tumor Volume Definition?. <i>Blood</i> , 2011 , 118, 5187-5187	2.2	1

71	The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry. <i>Blood</i> , 2012 , 120, 1611-1611	2.2	1
70	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). <i>Blood</i> , 2013 , 122, 3049-3049	2.2	1
69	The Role Of Qualitative FDG-PET Assessment Using The 5 Point Deauville Scale For Postinduction Response Assessment In Patients With Follicular Lymphoma. A Study From The Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2013 , 122, 4295-4295	2.2	1
68	Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2014 , 124, 499-499	2.2	1
67	Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021 , 138, 811-811	2.2	1
66	Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi. <i>Blood</i> , 2018 , 132, 2066-2066	2.2	1
65	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 3049-3049	2.2	1
64	Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori-Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial). <i>Blood</i> , 2011 , 118, 958-958	2.2	1
63	New information flows for cancer registries: testing the use of laboratory data in the province of Reggio Emilia, Italy. <i>European Journal of Cancer Prevention</i> , 2020 , 29, 548-555	2	1
62	A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS7568-TPS7568	2.2	1
61	What's new in peripheral T-cell lymphomas. <i>Hematological Oncology</i> , 2021 , 39 Suppl 1, 52-60	1.3	1
60	Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2021 , 39, 205-214	1.3	1
59	Personalised approach in follicular lymphoma. <i>Lancet Oncology, The</i> , 2018 , 19, 1431-1432	21.7	1
58	Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021 , 138, 305-305	2.2	0
57	Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi. <i>Blood</i> , 2015 , 126, 2686-2686	2.2	0
56	Outcome of Elderly Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Prospectively Identified by Comprehensive Geriatric Assessment (CGA). Results From a Study of the Intergroup Italiano Linfomi (IIL). <i>Blood</i> , 2010 , 116, 1771-1771	2.2	0
55	Reply to T.P. Vassilakopoulos et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3585-3586	2.2	0
54	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021 , 1-9	2.8	0

53	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.. <i>Frontiers in Oncology</i> , 2021 , 11, 789891	5.3	o
52	Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2350-2353	4.4	
51	Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo". <i>Supportive Care in Cancer</i> , 2020 , 28, 5125-5137	3.9	
50	Positron emission tomography-computed tomography in follicular lymphoma: "one fit for all"?. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1191-2	1.9	
49	Follicular lymphoma 2013 , 216-230		
48	The role of anthracyclines in follicular lymphomas. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2267-8	1.9	
47	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide □ Response to mileskin et al.. <i>British Journal of Haematology</i> , 2003 , 123, 748-748	4.5	
46	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , 2020 , 136, 30-31	2.2	
45	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. <i>Blood</i> , 2021 , 138, 41-41	2.2	
44	A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2004 , 104, 3261-3261 ^{2,2}	2.2	
43	Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.. <i>Blood</i> , 2006 , 108, 4628-4628	2.2	
42	Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. <i>Blood</i> , 2006 , 108, 4703-4703	2.2	
41	Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.. <i>Blood</i> , 2006 , 108, 2442-2442	2.2	
40	Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.. <i>Blood</i> , 2006 , 108, 2763-2763 ^{2,3}	2.2	
39	IELSG Phase II Studies of Bortezomib in Malt Lymphomas.. <i>Blood</i> , 2007 , 110, 2580-2580	2.2	
38	Front-Line Treatment of Low-Grade Non-Follicular Non-Hodgkin Lymphoma (Final Report of Gisl LL02 Trial).. <i>Blood</i> , 2007 , 110, 2332-2332	2.2	
37	Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 1628-1628	2.2	
36	Home Care of Acute Leukemia Patients: From Active Therapy to End-of-Life and Palliative Care. a Three-Year Experience of a Single Centre. <i>Blood</i> , 2018 , 132, 5867-5867	2.2	

- 35 Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. *Blood*, **2019**, 134, 1539-1539 2.2
- 34 Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. *Journal of Clinical Oncology*, **2014**, 32, 8530-8530 2.2
- 33 Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.. *Journal of Clinical Oncology*, **2014**, 32, 8502-8502 2.2
- 32 Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry. *Blood*, **2014**, 124, 5400-5400 2.2
- 31 Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases. *Blood*, **2014**, 124, 5411-5411 2.2
- 30 Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL. *Blood*, **2014**, 124, 4429-4429 2.2
- 29 Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Treated with Chemo-Immunotherapy. *Blood*, **2014**, 124, 3027-3027 2.2
- 28 Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study. *Blood*, **2015**, 126, 5032-5032 2.2
- 27 Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. *Blood*, **2015**, 126, 3919-3919 2.2
- 26 Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma. *Blood*, **2015**, 126, 581-581 2.2
- 25 Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. *Blood*, **2015**, 126, 701-701^{2,2}
- 24 Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. *Blood*, **2016**, 128, 690-690 2.2
- 23 Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy. *Blood*, **2008**, 112, 3753-3753 2.2
- 22 Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients.. *Blood*, **2008**, 112, 1012-1012 2.2
- 21 A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection. *Blood*, **2008**, 112, 3054-3054 2.2
- 20 Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative.. *Blood*, **2009**, 114, 1259-1259^{2,2}
- 19 Pretransplantation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).. *Blood*, **2009**, 114, 3707-3707 2.2
- 18 Use of FDG Positron Emission Tomography (FDG-PET) in Patients with Hodgkin Lymphoma (HL): a Population Based Study.. *Blood*, **2009**, 114, 5023-5023 2.2

17	Incidence Rate of Thromboembolic Events (TE) In a Prospectively Evaluated Population of Patients with Lymphoma Enrolled In First Line Treatment Clinical Trials: a Report From the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Blood</i> , 2010 , 116, 4208-4208	2.2
16	Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IPI 2B) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis. <i>Blood</i> , 2011 , 118, 1606-1606	2.2
15	The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011 , 118, 2651-2651	2.2
14	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. <i>Blood</i> , 2011 , 118, 2636-2636	2.2
13	What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study Refoll by the Fondazione Italiana Linfomi (FIL) On 548 Patients. <i>Blood</i> , 2012 , 120, 154-154	2.2
12	Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (1CT01000070). <i>Blood</i> , 2012 , 120, 3611-3611	2.2
11	Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 4860-4860	2.2
10	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.. <i>Blood</i> , 2012 , 120, 2647-2647	2.2
9	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 3653-3653	2.2
8	Addition of Rituximab to Front-Line-Treatment Highly Improved the Outcome of Elderly Patients with Follicular Lymphoma: a Population Based-Study From the Modena Cancer Registry. <i>Blood</i> , 2012 , 120, 5077-5077	2.2
7	Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 3652-3652	2.2
6	Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 5088-5088	2.2
5	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. <i>Blood</i> , 2013 , 122, 1782-1782	2.2
4	New IMiD on the block. <i>Lancet Haematology,the</i> , 2020 , 7, e627-e629	14.6
3	PET Imaging. <i>Hematologic Malignancies</i> , 2021 , 41-49	0
2	The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. <i>Oncologist</i> , 2021 , 26, e1418-e1426	5.7
1	Reply to M. Shibusawa et al.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200177	2.2